Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gender Differences and Outcomes in Melanoma Patients

Gender Differences and Outcomes in Melanoma Patients IntroductionMelanoma is one of the most common cancers in younger people. The incidence of cutaneous melanoma is increasing in patients of both sexes, with female patients generally living longer than their male counterparts. The aim of this retrospective study was to evaluate and confirm the sex-based difference in survival of melanoma patients and the relationship of this difference with pathological features.MethodsA total of 1023 patients who had been treated at the Department of Medical Oncology, Università Politecnica Marche (Ancona, Italy) and the INRCA-IRCCS Department of Dermatology (Ancona, Italy) between 1987 and 2014 were enrolled in the study.ResultsIn terms of stage of disease at onset, there was a significant difference in disease-free survival (DFS) and overall survival (OS) in favor of female patients in disease stage I (P  = 0.001 and P  = 0.01, respectively) and II (P  = 0.02 and P  = 0.009, respectively). Female patients also showed a significant improvement in 12-year DFS and 12-year OS adjusted for pathological features (Breslow thickness, ulceration, “absent” tumor-infiltrating lymphocyte (TIL) melanomas, “non-brisk” TIL pattern). Globally, female patients had an advantage over with male patients in both DFS and OS (P  < 0.001).ConclusionsOur results show that women have a survival benefit over with men after adjustment for many variables that can reduce mortality risk in female melanoma patients. In a future investigation we wish to examine possible biological sex differences in tumor–host interactions. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Loading next page...
 
/lp/springer-journals/gender-differences-and-outcomes-in-melanoma-patients-ePxJ00eq0r
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2020
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-020-00109-1
Publisher site
See Article on Publisher Site

Abstract

IntroductionMelanoma is one of the most common cancers in younger people. The incidence of cutaneous melanoma is increasing in patients of both sexes, with female patients generally living longer than their male counterparts. The aim of this retrospective study was to evaluate and confirm the sex-based difference in survival of melanoma patients and the relationship of this difference with pathological features.MethodsA total of 1023 patients who had been treated at the Department of Medical Oncology, Università Politecnica Marche (Ancona, Italy) and the INRCA-IRCCS Department of Dermatology (Ancona, Italy) between 1987 and 2014 were enrolled in the study.ResultsIn terms of stage of disease at onset, there was a significant difference in disease-free survival (DFS) and overall survival (OS) in favor of female patients in disease stage I (P  = 0.001 and P  = 0.01, respectively) and II (P  = 0.02 and P  = 0.009, respectively). Female patients also showed a significant improvement in 12-year DFS and 12-year OS adjusted for pathological features (Breslow thickness, ulceration, “absent” tumor-infiltrating lymphocyte (TIL) melanomas, “non-brisk” TIL pattern). Globally, female patients had an advantage over with male patients in both DFS and OS (P  < 0.001).ConclusionsOur results show that women have a survival benefit over with men after adjustment for many variables that can reduce mortality risk in female melanoma patients. In a future investigation we wish to examine possible biological sex differences in tumor–host interactions.

Journal

Oncology and TherapySpringer Journals

Published: Jun 4, 2020

There are no references for this article.